CDTX Cidara Therapeutics Inc

Cidara Therapeutics Inc mainly develops anti-infective drugs in the United States. It attends to serious fungal infections through its drug candidates and proprietary immunotherapy technology platform, CloudbreakTM.

$1.52
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/15/2015
Outstanding shares:  66,686,054
Average volume:  767,050
Market cap:   $96,694,778
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    171757107
ISIN:        US1717571079
Sedol:      
Valuation   (See tab for details)
PE ratio:   -2.06
PB ratio:   4.76
PS ratio:   2.10
Return on equity:   4,084.46%
Net income %:   -102.65%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy